P396: Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life settingECCO'21 VirtualYear: 2021
Authors: De Somer, T.(1);Deprez, N.(2);Baert, D.(1);Deceuninck, M.(3);Huys, I.(1);Mattens, V.(4);Sterckx, A.(4);Vanden Branden, S.(4);Vanderstraeten , E.(1);Vandervoort , J.(4);Van Heddegem, N.(1);Dewint, P.(1);
(1)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(2)Ghent University, Gastroenterology, Gent, Belgium;(3)AZ Sint-Vincentius, Gastroenterology, Deinze, Belgium;(4)OLV Ziekenhuis Aalst, Gastroenterology, Aalst, Belgium
P397: Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labelingECCO'21 VirtualYear: 2021
Authors: Iacucci, M.(1);Grisan, E.(2);Labarile, N.(1);Nardone, O.(1);Smith, S.C.(1);Jeffery, L.(1);Ghosh, S.(1);Buda, A.(3);
(1)University Hospitals NHS Foundation Trust and University of Birmingham- Birmingham- UK, Institute Translational of Medicine- Institute of Immunology and Immunotherapy and NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom;(2)School of Engineering- London South Bank University- London SE1 0AA- UK, Department of Engineering, London, United Kingdom;(3)S. Maria del Prato Hospital- Feltre- Italy, Department of Gastrointestinal Oncological Surgery-, Feltre, Italy
P398: Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with AnaemiaECCO'21 VirtualYear: 2021
Authors: Bevers, N.(1);van de Vijver , E.(2);Aliu , A.(1);Rezazadeh Ardabili , A.(3);Rosias , P.(1);Busari , J.(4);Stapelbroek , J.(5);Bertrams , I.(6); van der Feen , C.(7);Oudshoorn , A.(8);Teklenburg , S.(9);Escher , J.(10);Vande Velde , S.(11);Winkens , B.(12);Raijmakers , M.(13);Vreugdenhil , A.(14); Pierik , M.(3);van Rheenen , P.(15);
(1)Zuyderland Medical Centre, Paediatrics, Heerlen, The Netherlands;(2)University Hospital Antwerp, Paediatric Gastroenterology- Hepatology- and Nutrition, Edegem, Belgium;(3)Maastricht University Medical Centre, Gastroenterology and Hepatology, Maastricht, The Netherlands;(4)Dr. Horacio E. Oduber Hospital, General Paediatrics and Adolescent care, Oranjestad, Aruba;(5)Catharina Hospital, Paediatrics, Eindhoven, The Netherlands;(6)Maxima Medical Centre, Paediatrics, Veldhoven, The Netherlands;(7)Jeroen Bosch Hospital, Paediatrics, 's-Hertogenbosch, The Netherlands;(8)Gelre Hospital, Paediatrics, Apeldoorn, The Netherlands;(9)Isala Clinics, Paediatrics, Zwolle, The Netherlands;(10)Erasmus Medical Centre, Paediatric Gastroenterology- Hepatology- and Nutrition, Rotterdam, The Netherlands;(11)University Hospital Ghent, Internal Medicine and Paediatrics, Ghent, Belgium;(12)Maastricht University, Methodology and Statistics, Maastricht, The Netherlands;(13)Zuyderland Medical Centre, Clinical Chemistry and Hematology, Heerlen, The Netherlands;(14)Maastricht University Medical Centre, Paediatric Gastroenterology and Hepatology, Maastricht, The Netherlands;(15)University Medical Centre Groningen, Paediatric Gastroenterology- Hepatology- and Nutrition, Groningen, The Netherlands; Popeye Study
P399: Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre studyECCO'21 VirtualYear: 2021
Authors: De Gregorio, M.(1,2);Lee, T.(1);Krishnaprasad, K.(1,3);Amos, G.(4,5);An, Y.K.(4,6);Bastian-Jordan, M.(4,5);Begun, J.(6,7);Borok, N.(8,9);Brown, D.J.M.(10);Cheung, W.(11);Connor, S.(12,13,14);Gerstenmaier, J.(11);Gilbert, L.E.(15);Gilmore, R.(16);Gu, B.(12,14,17);Kutaiba, N.(18,19);Lee, A.(20,21);Mahy, G.(22);Srinivasan, A.(16,23,24);Thin, L.(25,26);Thompson, A.(1,2);Welman, C.J.(27);Yong, E.X.(28);De Cruz, P.(2,16);van Langenberg, D.(23,24);Sparrow co-lead senior author, M.(15,24);Ding, N.S.(1,2);
(1)St Vincent's Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia;(2)University of Melbourne, Medicine, Parkville, Australia;(3)QIMR Berghofer Medical Research Institute, Gut Health Lab, Brisbane, Australia;(4)University of Queensland, Medicine, St Lucia, Australia;(5)Queensland X-ray, Medical Imaging, Brisbane, Australia;(6)Mater Hospital Brisbane, Gastroenterology, South Brisbane, Australia;(7)University of Queensland, Mater Research Institute, St Lucia, Australia;(8)Liverpool Hospital, Medical Imaging, Liverpool, Australia;(9)South Western Sydney Local Health District, Medicine, Liverpool, Australia;(10)Townsville University Hospital, Medical Imaging, Douglas, Australia;(11)Alfred Health, Medical Imaging, Melbourne, Australia;(12)Liverpool Hospital, Gastroenterology and Hepatology, Liverpool, Australia;(13)Ingham Institute for Applied Medical Research, Medicine, Liverpool, Australia;(14)University of New South Wales, South Western Sydney Clinical School, Sydney, Australia;(15)Alfred Health, Gastroenterology, Melbourne, Australia;(16)Austin Health, Gastroenterology, Heidelberg, Australia;(17)Royal Prince Alfred Hospital, Gastroenterology and Hepatology, Camperdown, Australia;(18)Austin Health, Radiology, Heidelberg, Australia;(19)Eastern Health, Radiology, Box Hill, Australia;(20)Imaging Associates Eastern Health, Medical Imaging, Melbourne, Australia;(21)Peter MacCallum Cancer Centre, Cancer Imaging, Melbourne, Australia;(22)Townsville University Hospital, Gastroenterology, Douglas, Australia;(23)Eastern Health, Gastroenterology, Box Hill, Australia;(24)Monash University, Medicine, Clayton, Australia;(25)Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia;(26)University of Western Australia, School of Medicine and Pharmacology, Crawley, Australia;(27)Fiona Stanley Hospital, Medical Imaging, Murdoch, Australia;(28)St Vincent's Hospital Melbourne, Medical Imaging, Fitzroy, Australia; FISCAL
P400: Bowel ultrasonography, a non invasive easy-to-use method to predict the need to step-up therapy in inflammatory bowel disease patientsECCO'21 VirtualYear: 2021
Authors: Les, A.(1);Iacob, R.(1);Cotruta, B.(1);Saizu, R.(1);Gheorghe, L.(1);Gheorghe, C.(1);
(1)Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania
P401: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort studyECCO'21 VirtualYear: 2021
Authors: Lamb, C.A.(1,2);Sebastian, S.(3,4);Kent, A.J.(5);Segal, J.P.(6);Gonzalez, H.A.(3,4);Brookes, M.J.(7,8);Mehta, S.J.(9);Subramanian, S.(10,11);Bhala, N.(12,13);Hicks, L.C.(6);Conley, T.E.(10);Patel, K.V.(14);Walker, G.J.(15);Kennedy, N.A.(16,17);
(1)Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom;(2)Newcastle upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom;(3)Hull University Teaching Hospitals NHS Trust, Department of Gastroenterology, Hull, United Kingdom;(4)University of Hull, Faculty of Health Sciences, Hull, United Kingdom;(5)King’s College Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(6)Imperial College Healthcare NHS Trust, Department of Gastroenterology, London, United Kingdom;(7)Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(8)University of Wolverhampton, Research Institute in Healthcare Science, Wolverhampton, United Kingdom;(9)University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(10)Royal Liverpool and Broadgreen University Hospitals NHS Trust, Department of Gastroenterology, Liverpool, United Kingdom;(11)Institute of Translational Medicine, Cellular and Molecular Physiology, Liverpool, United Kingdom;(12)Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom;(13)University of Birmingham, Institute of Applied Health Research, Birmingham, United Kingdom;(14)St George’s University Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(15)Torbay and South Devon NHS Foundation Trust, Department of Gastroenterology, Torquay, United Kingdom;(16)Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(17)University of Exeter, Exeter IBD Research Group, Exeter, United Kingdom; PREPARE-IBD Study Group
P403: Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving.ECCO'21 VirtualYear: 2021
Authors: Ferreiro Iglesias, R.(1);Hernández Camba, A.(2);Saldaña, R.(3);Rodríguez-Lago, I.(4);Zabana, Y.(5);Barreiro-de Acosta , M.(1);
(1)Servicio de Gastroenterología. Hospital Clínico Universitario de Santiago. Fundación Instituto de Investigación Sanitaria de Santiago de Compostela IDIS-, Gastroenterology Department, Santiago, Spain;(2)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology Department, Tenerife, Spain;(3)ACCU Spain, Managing Director, Madrid, Spain;(4)Hospital Universitario de Galdakao, Gastroenterology Department, Bilbao, Spain;(5)Hospital Universitari Mútua de Terrassa. Centro Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department, Barcelona, Spain; On behalf of Young Group of GETECCU and ACCU
P404: Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in GermanyECCO'21 VirtualYear: 2021
Authors: Picker, N.(1);Bokemeyer, B.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
(1)Ingress Health, HWM GmbH, Wismar, Germany;(2)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany;(3)IPAM, e.V., Wismar, Germany;(4)Galapagos, Biopharma Deutschland GmbH, München, Germany;(5)Galapagos, Nv, Mechelen, Belgium
P405: Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patientsECCO'21 VirtualYear: 2021
Authors: Thomas, D.(1);Compernolle, G.(1);Guedelha Sabino, J.P.(2,3);Ferrante, M.(2,3);Vermeire, S.(2,3);Declerck, P.(1);
(1)KU Leuven, Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Chronic Diseases- Metabolism and Ageing, Leuven, Belgium
P406: A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countriesECCO'21 VirtualYear: 2021
Authors: Kopylov, U.(1);Burisch , J.(2); Ben-Horin , S.(1);Braegger, F.(3);Fernández-Nistal , A.(4);Lara, N.(5);Vavricka , S.(6,7);
(1)Gastroenterology Institute- Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv, Israel;(2)Hvidvore University Hospital, Gastrounit- medical division, Hvidvore, Denmark;(3)Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International AG, Zürich, Switzerland;(4)Takeda Farmacéutica España S.A., Medical Department, Madrid, Spain;(5)IQVIA, Real World Evidence Solutions, Barcelona, Spain;(6)University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(7)Center for Gastroenterology und Hepatology AG, Center for Gastroenterology und Hepatology AG, Zürich, Switzerland
P407: Thiopurines: use them or lose them? Results of an international surveyECCO'21 VirtualYear: 2021
Authors: Sousa, P.C.(1);Ministro, P.(2);Armuzzi, A.(3,4);Dignass, A.(5);Høivik, M.L.(6);Magro, F.(7,8,9);
(1)Centro Hospitalar Tondela-Viseu, Department of Gastroenterology, Viseu, Portugal;(2)Centro Hospitalar Tondela-Viseu, Department of Gastroenterology, Viseu, Portugal;(3)Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(4)Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;(5)Agaplesion Markus Hospital- Goethe University, Department of Medicine I, Frankfurt/Main, Germany;(6)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;(7)Unit of Pharmacology and Therapeutics- University of Porto, Department of Biomedicine, Oporto, Portugal;(8)Centre for Drug Discovery and Innovative Medicines, MedInUP, Oporto, Portugal;(9)São João University Hospital, Department of Gastroenterology, Oporto, Portugal
P408: Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical SignificanceECCO'21 VirtualYear: 2021
Authors: Doherty, J.(1);Varley, R.(1);Healy, M.(2);Dunne, C.(1);Mac Carthy, F.(1);McKiernan, S.(1);Hartery, K.(1);Kevans, D.(1);
(1)St James Hospital, Department of Gastroenterology, Dublin 8, Ireland;(2)St James Hospital, Department of Biochemistry, Dublin 8, Ireland
P409: Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING studyECCO'21 VirtualYear: 2021
Authors: D’Haens, G.R.(1);Dubinsky, M.C.(2);Regueiro, M.(3);Santana, G.O.(4);Torres, J.(5);Kulisek, N.(6);Gardiner, S.(7);Mundayat, R.(7);Paulissen, J.(7);Lawendy, N.(6);Su, C.(6);Modesto, I.(7);Sandborn, W.J.(8);
(1)Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands;(2)Icahn School of Medicine at Mount Sinai, New York, New York, United States;(3)Department of Gastroenterology- Hepatology and Nutrition, Cleveland Clinic, Cleveland- Ohio, United States;(4)University of the State of Bahia, Salvador, Bahia, Brazil;(5)Surgical Department- Gastroenterology Division, Hospital Beatriz Ângelo- Loures, and Faculdade de Medicina- Universidade de Lisboa- Lisbon, Portugal;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Division of Gastroenterology, University of California, San Diego- La Jolla- California, United States
P410: Which patients with established Crohn's disease benefit most from the use of the Patency capsule test prior to small bowel capsule endoscopy?ECCO'21 VirtualYear: 2021
Authors: Elosua Gonzalez, A.(1);Rullan Iriarte, M.(1);Rubio Iturria, S.(2);Rodríguez Gutiérrez, C.(2);Vicuña Arregui, M.(2);Elizalde Apesteguía, I.(2);Aznárez Barrio, M.R.(2);Juanmartiñena Fernández, J.F.(2);Nantes Castillejo, Ó.(2);Fernández-Urién, I.(2);
(1)Hospital García Orcoyen, Gastroenterology, Estella, Spain;(2)Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain
P412: Effectiveness of ustekinumab in fistulising perianal Crohn´s disease refractory or intolerant to anti-TNFECCO'21 VirtualYear: 2021
Authors: Carpio, D.(1);Calviño-Suarez , C.(2);Martínez-Cadilla , J.(3);Molina , G.(4);Vázquez-Rey , M.T.(5);Martí , E.(6);Fernández-Salgado , E.(1);Barreiro-de Acosta , M.(2);Hernández , V.(3);Echarri , A.(4);Diz-Lois , M.T.(5);Baz , A.(6);
(1)Complejo Hospitalario Universitario de Pontevedra, Gastroenterology, Pontevedra, Spain;(2)Complexo Hospitalario Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(3)Complexo Hospitalario Universitario de Vigo, Gastroenterology, Vigo, Spain;(4)Complexo Hospitalario Universitario de Ferrol, Gastrenterology, Ferrol, Spain;(5)Complexo Hospitalario Universitario de A Coruña, Gastroenterology, A Coruña, Spain;(6)Hospital Universitario Lucus Augusti, Gastroenterology, Lugo, Spain; EIGA (Grupo Galego de Enfermedad Inflamatoria Intestinal)
P413: Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn`s disease.ECCO'21 VirtualYear: 2021
Authors: Ladrón Abia, P.(1); Alonso, N.(2);Beltrán, B.(1);Minguez, A.(1);Sáez-González, E.(1);Pons-Beltrán, V.(2);Nos, P.(1);Iborra, M.(1);
(1)Hospital Universitari i Politècnic La Fe, Gastroenterology Unit- Digestive Diseases Department, Valencia, Spain;(2)Hospital Universitari i Politècnic La Fe, Gastrointestinal Endoscopy Unit- Digestive Diseases Department, Valencia, Spain
P414: Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Mahmoud, R.(1);Schultheiss, J.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);Mahmmod, N.(2);van Boeckel, P.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1);
(1)University Medical Centre Utrecht, Division of Internal Medicine and Dermatology- Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)St. Antonius Hospital, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(3)Meander Medical Centre, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands
P415: Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agentsECCO'21 VirtualYear: 2021
Authors: Matsune, Y.(1);Kouyama, J.(1);Tsuru, Y.(1);Shimizu, K.(1);Asami, S.(1);Matsuyama, S.(1);Katsuki, S.(1);Ishihara, H.(1);Onizawa, R.(1);Shonai, S.(1);Tatsuno, M.(1);Nishikawa, Y.(1);Takeuchi, K.(1);Watanabe, M.(1);Nakamori, Y.(1);Hirayama, A.(1);Toyoda, J.(1);Ikeda, A.(1);Madarame, A.(1);Nishio, M.(1);Ogashiwa, T.(1);Matsubayashi, M.(1);Fujii, A.(1);Kimura, H.(1);Kunisaki, R.(1);
(1)Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan
